Medications for Alcohol Use Disorder: Treatment Options

FDA-Approved Medications for AUD

Three medications are FDA-approved for alcohol use disorder (AUD). They work through distinct mechanisms and can be used alone or in combination with behavioral therapies.

1. Disulfiram (Antabuse®)

Mechanism: Irreversibly inhibits aldehyde dehydrogenase (ALDH), the enzyme that metabolizes acetaldehyde (a toxic byproduct of alcohol). If alcohol is consumed, acetaldehyde accumulates, causing a severe, unpleasant reaction: flushing, throbbing headache, nausea, vomiting, sweating, tachycardia, hypotension, dyspnea, and anxiety.

Role: Aversion therapy/deterrent. Most effective for highly motivated patients committed to abstinence who want a "safety net."

Key considerations: Must be alcohol-free for 12+ hours before first dose. Reaction can occur with alcohol in sauces, mouthwash, cough syrup. Contraindicated in severe heart disease, psychosis, pregnancy. Requires daily supervised dosing for best adherence.

2. Naltrexone (ReVia® oral; Vivitrol® monthly injection)

Mechanism: Competitive antagonist at mu-opioid receptors. Blocks the endogenous opioid release triggered by alcohol, reducing the rewarding "buzz" and craving.

Role: Reduces heavy drinking days and relapse risk; supports both abstinence and controlled drinking goals.

Key considerations: Oral: 50 mg daily. Injectable: 380 mg IM monthly—improves adherence. Must be opioid-free for 7–10 days before starting (precipitated withdrawal risk). Monitor LFTs (rare hepatotoxicity at high doses). Generally well-tolerated.

3. Acamprosate (Campral®)

Mechanism: Modulates glutamatergic (NMDA) and GABAergic neurotransmission, restoring balance disrupted by chronic alcohol exposure. Reduces post-acute withdrawal symptoms (anxiety, insomnia, restlessness) that drive relapse.

Role: Maintenance of abstinence after detoxification. Less effective for reducing heavy drinking if still drinking.

Key considerations: 666 mg (two 333 mg tablets) TID. Renal dosing required (contraindicated if CrCl <30). No abuse potential; no interaction with alcohol. Start after detox (day 5–7). GI side effects (diarrhea) common initially.

Off-Label / Investigational Options

4. Topiramate (Topamax®)

Anticonvulsant with multiple actions (GABA enhancement, glutamate inhibition, carbonic anhydrase inhibition). Multiple RCTs show reduced heavy drinking days and increased abstinence. Side effects: cognitive dulling, paresthesias, weight loss, kidney stones. Requires slow titration.

5. Baclofen (Lioresal®)

GABA-B agonist. Reduces craving and consumption, especially in patients with liver disease (safe in cirrhosis). Evidence mixed but promising in some European studies. Off-label; requires careful titration and monitoring for sedation, withdrawal if stopped abruptly.

6. Others under investigation:

  • Varenicline (nicotinic partial agonist) – reduces alcohol craving in smokers with AUD.
  • Gabapentin – may help with sleep/anxiety in early abstinence.
  • Psychedelics (psilocybin, MDMA) – early-phase trials with psychotherapy.

Integrated Treatment: The Standard of Care

Medications are one component of a comprehensive plan. The highest success rates come from combining pharmacotherapy with:

  • Evidence-based behavioral therapies: CBT, Motivational Enhancement Therapy (MET), Community Reinforcement Approach (CRA), Contingency Management.
  • Mutual support: AA, SMART Recovery, LifeRing, Refuge Recovery.
  • Treatment of co-occurring disorders: Depression, anxiety, PTSD, chronic pain.
  • Social determinants: Housing, employment, legal, family support.

Choosing the Right Medication

Decision factors: patient goals (abstinence vs. reduction), medical comorbidities (liver/kidney function), adherence likelihood, side effect profile, cost/access, and clinician expertise. AUD is a chronic, relapsing condition—treatment should be long-term, flexible, and patient-centered. There is no "one size fits all."

Drug Addiction - Related Articles